|
|
Home
The Word Brain
|
My Amedeo
FAQ
Privacy
About
|
|
|||||||||
Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual |
| Bladder Cancer |
| Single Articles |
AMEDEO Bladder Cancer is free of charge.
A case of plasmacytoid urothelial carcinoma with characteristic radiological
findings.
Abdom Radiol (NY). 2025;50:5376-5381.
PubMed
Abstract available
An Organoid Biosensing Platform for Personalized Prognosis of Bladder Cancer.
ACS Nano. 2025 Oct 30. doi: 10.1021/acsnano.5c09883.
PubMed
Abstract available
Nanozyme-Based Biomimetic Intelligent Immune Organelles for the Treatment of
Bladder-Metastasized Tumors.
Adv Mater. 2025;37:e11181.
PubMed
Abstract available
A Novel FGFR3-Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis
through the cGAS-STING Pathway in Bladder Cancer.
Adv Sci (Weinh). 2025 Oct 30:e09933. doi: 10.1002/advs.202509933.
PubMed
Abstract available
Letter to the Editor Regarding "Assessing the Influence of Bladder Cancer on
Upper Tract Urothelial Carcinoma Prognoses Following Radical Nephroureterectomy:
A Retrospective, Propensity Score-Based Multicenter Cohort Study".
Ann Surg Oncol. 2025 Oct 25. doi: 10.1245/s10434-025-18611.
PubMed
Management of Bladder Cancer During Pregnancy: A Narrative Review.
Anticancer Res. 2025;45:4689-4695.
PubMed
Abstract available
Colovesical Fistula Management and the Role of Cystoscopy: A Single Institution
Experience.
ANZ J Surg. 2025;95:2148-2154.
PubMed
Abstract available
A Phase 2 Prospective Trial of Capecitabine Plus Oxaliplatin as First-Line
Therapy for Advanced Gall Bladder Cancers.
Asian Pac J Cancer Prev. 2025;26:3761-3767.
PubMed
Abstract available
Beijing Da Xue Xue Bao Yi Xue Ban
[Prognostic analysis of laparoscopic simultaneous radical cystectomy and
nephroureterectomy].
Beijing Da Xue Xue Bao Yi Xue Ban. 2025;57:961-966.
PubMed
Abstract available
Bladder cancer journal as official IBCN partner; strengthening global
collaboration in bladder cancer.
Bladder Cancer. 2025;11:23523735251384859.
PubMed
Development and external validation of a FISH-clinical nomogram for predicting
overall survival in bladder cancer patients after radical cystectomy.
BMC Cancer. 2025;25:1648.
PubMed
Abstract available
Imidacloprid contributes to bladder cancer progression: preliminary evidence
based on network toxicology, machine learning and molecular docking.
BMC Pharmacol Toxicol. 2025;26:180.
PubMed
Abstract available
The utility of radiopharmaceutical uptake in the bladder neck and prostate on
preoperative FDG PET/CT in determining urethral surgical margin positivity in
patients undergoing radical cystoprostatectomy for bladder cancer.
BMC Urol. 2025;25:271.
PubMed
Abstract available
The incidence and risk factors of urinary tract infections in patients undergoing
bladder tumor resection: a systematic review and meta-analysis.
BMC Urol. 2025;25:267.
PubMed
Abstract available
Trends in the incidence of cancers of the male genital system and urinary bladder
in Harare, Zimbabwe, 1990-2019.
Cancer Causes Control. 2025;36:1579-1587.
PubMed
Abstract available
Single-cell stemness analysis highlights Midkine-LRP1 pathway and identifies new
bladder cancer subtypes.
Cancer Cell Int. 2025;25:376.
PubMed
Abstract available
Bacterial nanoparticles as a potent and safe alternative to BCG for bladder
cancer immunotherapy.
Cancer Gene Ther. 2025 Oct 30. doi: 10.1038/s41417-025-00984.
PubMed
Abstract available
Expression of Glucocorticoid Receptor and FOXO1/phospho-FOXO1 in Bladder Cancer
as Independent Prognosticators.
Cancer Genomics Proteomics. 2025;22:850-862.
PubMed
Abstract available
Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial
Carcinoma in Japan: Subgroup Analyses of Post-Marketing Surveillance Data by Age,
Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy.
Cancer Med. 2025;14:e71177.
PubMed
Abstract available
Real-World Outcomes of Avelumab Maintenance Therapy in Patients With Curatively
Unresectable Urothelial Carcinoma in Japan: Results From the Final Analysis of
Postmarketing Surveillance.
Cancer Med. 2025;14:e71264.
PubMed
Abstract available
EXPRESSION OF CONCERN: Long Non-coding RNA Urothelial Cancer-associated 1
Promotes Bladder Cancer Cell Migration and Invasion by Way of the
hsa-miR-145-ZEB1/2-FSCN1 Pathway.
Cancer Sci. 2025 Oct 29. doi: 10.1111/cas.70241.
PubMed
Lead Exposure and Bladder Cancer: Molecular Insights from TCGA RNA-Seq and
Toxicogenomic Integration.
Cancers (Basel). 2025;17:3291.
PubMed
Abstract available
YTHDC2 suppresses bladder cancer by inhibiting SOX2-mediated tumor plasticity.
Cell Death Dis. 2025;16:765.
PubMed
Abstract available
A Systematic Review and Meta-Analysis of the Effectiveness and Safety of Immune
Checkpoint Inhibitors in Patients With BCG-Unresponsive Non-Muscle-Invasive
Bladder Cancer.
Clin Genitourin Cancer. 2025 Sep 25:102445. doi: 10.1016/j.clgc.2025.102445.
PubMed
Abstract available
Comparison of Remimazolam and Sevoflurane on Perioperative Body Temperature
Changes in Older Patients Undergoing Transurethral Resection of Prostate or
Bladder Tumors Under General Anesthesia: A Randomized Prospective Clinical Trial.
Clin Interv Aging. 2025;20:1811-1820.
PubMed
Abstract available
SEOM-SOGUG clinical guideline for urothelial cancer (2025).
Clin Transl Oncol. 2025;27:4142-4159.
PubMed
Abstract available
A Systematic Literature Review of Real-World Treatment Effectiveness and Economic
and Humanistic Burden in Patients With Muscle-Invasive Bladder Cancer Who
Underwent Radical Cystectomy.
Clinicoecon Outcomes Res. 2025;17:729-742.
PubMed
Abstract available
Leser-Trelat Sign as an Initial Manifestation of Synchronous Prostate and Bladder
Cancer.
Cureus. 2025;17:e93325.
PubMed
Abstract available
Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients
with Urothelial Carcinoma of the Bladder: A Pilot Study.
Curr Oncol. 2025;32:534.
PubMed
Abstract available
Systematic review and meta-analysis corrected for history of smoking tobacco
identifies type 1 diabetes as a possible risk factor for bladder cancer.
Diabetes Res Clin Pract. 2025 Oct 29:112976. doi: 10.1016/j.diabres.2025.112976.
PubMed
Abstract available
Reply to Behzad Jazayeri, Xuefeng Wang, and Roger Li's Letter to the Editor re:
Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer
Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
Non-muscle-invasive B
Eur Urol. 2025 Oct 23:S0302-2838(25)04739-6. doi: 10.1016/j.eururo.2025.
PubMed
Re: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, et al.
TAR-200 for Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive
Bladder Cancer: Results from the Phase IIb SunRISe-1 Study. J Clin Oncol. In
press. https://doi.
Eur Urol Focus. 2025 Oct 25:S2405-4569(25)00286.
PubMed
A Urologist's Guide to Managing Bladder Cancer in Patients Who Smoke.
Eur Urol Focus. 2025 Oct 27:S2405-4569(25)00287.
PubMed
Abstract available
Systematic Review of the Definition of Cure and of Curative-intent Treatments in
Early Bladder Cancer.
Eur Urol Oncol. 2025 Oct 30:S2588-9311(25)00256.
PubMed
Abstract available
Sequential intravesical Bacillus Calmette-Guerin and mitomycin C applied with
electromotive drug administration therapy for non-muscle invasive bladder cancer.
Front Oncol. 2025;15:1682918.
PubMed
Abstract available
Analysis of risk factors for ureteral stricture and tumor recurrence after
transurethral resection of bladder tumor in paraureteral bladder cancer.
Front Surg. 2025;12:1680837.
PubMed
Abstract available
Integrative Analysis of Biomarkers for Cancer Stem Cells in Bladder Cancer and
Their Therapeutic Potential.
Genes (Basel). 2025;16:1146.
PubMed
Abstract available
miR-124 Targets EGFR and Attenuates Growth and Invasion in Bladder Cancer Cells.
In Vivo. 2025;39:3216-3225.
PubMed
Abstract available
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate
of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER
Study.
In Vivo. 2025;39:3381-3393.
PubMed
Abstract available
The expression of p53 in urothelial carcinoma of bladder: An immunohistochemical
study.
Indian J Pathol Microbiol. 2025;68:492-497.
PubMed
Abstract available
PMDA regulatory update on approval and revision of the precautions for use of
anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib
for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for
bladder cancer
Int J Clin Oncol. 2025 Oct 25. doi: 10.1007/s10147-025-02901.
PubMed
First-line treatment options for metastatic urothelial carcinoma: balancing
efficacy, safety, and individual values and preferences through shared decision
making.
Int J Clin Oncol. 2025;30:2161-2167.
PubMed
Abstract available
The clinical relevance of tertiary lymphoid structures in assessing treatment
response in muscle invasive bladder cancer.
Int J Radiat Oncol Biol Phys. 2025 Oct 22:S0360-3016(25)06329.
PubMed
Abstract available
Comment on "Correlation of noninvasive imaging of tumour-infiltrating lymphocytes
with survival and BCG immunotherapy response in patients with bladder cancer: a
multicentre cohort study".
Int J Surg. 2025 Oct 28. doi: 10.1097/JS9.0000000000003680.
PubMed
Bladder-sparing therapy for high-tumor-burden non-muscle invasive bladder cancer:
outcomes from high-tumor-burden NMIBC program.
Int Urol Nephrol. 2025 Oct 28. doi: 10.1007/s11255-025-04873.
PubMed
Abstract available
Extracellular Vesicle-Mediated Regulation of H3C14 Contributes to Gemcitabine
Resistance in Bladder Cancer.
J Extracell Vesicles. 2025;14:e70179.
PubMed
Abstract available
Diseases burden and trends of bladder cancer attributable to behavioral and
metabolic factors among global and Chinese population, 1990-2021: results from
the global burden of disease study 2021.
J Health Popul Nutr. 2025;44:377.
PubMed
Abstract available
Radiomics-Based Preoperative Assessment of Muscle-Invasive Bladder Cancer Using
Combined T2 and ADC MRI: A Multicohort Validation Study.
J Imaging. 2025;11:342.
PubMed
Abstract available
Comparing quality of life after robot assisted versus open radical cystectomy: A
systematic review.
J Robot Surg. 2025;19:712.
PubMed
Abstract available
Outcomes Among Rural and Urban Patients with High-risk NMIBC: Results from the
Canadian Bladder Cancer Information System (CBCIS).
J Urol. 2025 Oct 30:101097JU0000000000004836. doi: 10.1097/JU.0000000000004836.
PubMed
Abstract available
Analysis of HER2 Expression in Different Histological Subtypes and IHC-Based
Molecular Variants of Muscle-Invasive Bladder Carcinoma.
Medicina (Kaunas). 2025;61:1759.
PubMed
Abstract available
AISI, SIRI, and MLR in Predicting Surgical Outcomes After Radical Cystectomy:
Revisiting Inflammatory Risk Markers.
Medicina (Kaunas). 2025;61:1756.
PubMed
Abstract available
Extracellular vesicles-derived LncRNA MAFG-AS1 predicts clinical response to
pembrolizumab in patients with advanced urothelial carcinoma.
Mol Biol Rep. 2025;53:23.
PubMed
Abstract available
pQTL Mendelian randomization analysis combined with single-cell sequencing to
identify biomarkers and drug targets for bladder cancer.
Mol Clin Oncol. 2025;23:106.
PubMed
Abstract available
Exploring the Synthesis, Anti-Inflammatory and Anti-Tumor Potential of
4-Maleimidylphenyl-Hydrazide Derivatives.
Molecules. 2025;30:4035.
PubMed
Abstract available
E-ABIN: an explainable module for anomaly detection in biological networks.
NAR Genom Bioinform. 2025;7:lqaf135.
PubMed
Abstract available
Optimizing local control in the surgical management of bladder cancer.
Nat Rev Urol. 2025 Oct 30. doi: 10.1038/s41585-025-01098.
PubMed
Abstract available
ACTG1 driven splicing of P4HB gene enhances EMT and bladder cancer progression.
NPJ Precis Oncol. 2025;9:330.
PubMed
Abstract available
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global
survey.
Oncologist. 2025;30:oyaf333.
PubMed
Abstract available
UK multidisciplinary recommendations on use of combination first-line enfortumab
vedotin? and pembrolizumab in advanced urothelial carcinoma.
Oncologist. 2025;30:oyaf220.
PubMed
Abstract available
beta2-integrins as biomarkers in urothelial cancer.
PLoS One. 2025;20:e0326015.
PubMed
Abstract available
Bladder Cancer and Vesical Imaging-Reporting and Data System: An Updated Review.
Radiol Clin North Am. 2025;63:923-940.
PubMed
Abstract available
A novel spatial framework to validate arsenic exposure gene expression profiling
in bladder cancer using multiplex FISH and AI-powered digital pathology.
Sci Rep. 2025;15:37925.
PubMed
Abstract available
Multi-institutional validation of AI models for classifying urothelial neoplasms
in digital pathology.
Sci Rep. 2025;15:37215.
PubMed
Abstract available
Comprehensive analysis of coagulation-associated gene signature in bladder cancer
diagnosis, prognosis, and immunotherapy.
Sci Rep. 2025;15:37768.
PubMed
Abstract available
Mechanistic study of GALNT16 promoting malignant progression and metastasis in
bladder cancer: functional analysis and experimental validation.
Transl Androl Urol. 2025;14:2481-2497.
PubMed
Abstract available
En bloc transurethral resection versus conventional transurethral resection for
non-muscle invasive bladder cancer: a systematic review and meta-analysis.
Transl Androl Urol. 2025;14:2593-2605.
PubMed
Abstract available
Awareness, knowledge, and willingness about early detection of bladder cancer in
Saudi Arabia: a cross-sectional study.
Transl Androl Urol. 2025;14:2498-2509.
PubMed
Abstract available
Sex-based differences in bladder cancer: Functional, oncologic, and biological
considerations.
Urol Oncol. 2025 Oct 23:S1078-1439(25)00406.
PubMed
Molecular subtyping of advanced bladder cancer patients and patient-derived
organoids based on a 3-marker immunohistochemistry approach to evaluate
chemotherapy sensitivity.
Urol Oncol. 2025 Oct 27:S1078-1439(25)00393.
PubMed
Abstract available
Prognostic significance of lymph node yield in pelvic lymph node dissection for
bladder cancer: population-based study.
World J Surg Oncol. 2025;23:405.
PubMed
Abstract available
LINC01082 inhibits malignant phenotypes of bladder cancer through sponging
miR-1269a.
World J Surg Oncol. 2025;23:402.
PubMed
Abstract available
Updated cost-effectiveness analysis of first-line novel therapies in locally
advanced or metastatic urothelial carcinoma across the UK, US, and China.
World J Urol. 2025;43:657.
PubMed
Abstract available
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer
survival: a 20-year study.
World J Urol. 2025;43:636.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
